MannKind

United States
Hotevilla-Bacavi, Arizona, United States, 91355

Company profile

MannKind company profile

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA(R), is in the late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. It maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind.

Business identity

Phone number
(661)775-5300
Operating status
Active
Company type
For Profit
Employee range
251-500 employees
Revenue range
$10M-$100M
Founded
2001-01-01, Year

Headquarters

Postal code
91355
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
4
Total equity funding
$40M
Last funding
Post IPO Debt / $75M / 2025-08-06
Last equity funding
Post IPO Equity / $40M
Investors
3
Lead investors
2
Founders
1
Articles
269
Exited on
2004-08-06

Founders and investors

Founders

Alfred E. Mann

Lead investors

Blackstone GroupDeerfield Capital Management

Investors

Blackstone GroupDeerfieldDeerfield Capital Management